Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 19/20 | 0.68 |
| ▸ | EBP | Q15125 | 1/20 | 0.68 |
| ▸ | TP53 | P04637 | 1/20 | 0.63 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.63 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.63 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.63 |
| ▸ | DRD2 | P14416 | 1/20 | 0.63 |
| ▸ | TSHR | P16473 | 1/20 | 0.63 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.63 |
| ▸ | HTR2A | P28223 | 1/20 | 0.63 |
| ▸ | HTR2C | P28335 | 1/20 | 0.63 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.63 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.63 |
| ▸ | HTR2B | P41595 | 1/20 | 0.63 |
| ▸ | MTOR | P42345 | 1/20 | 0.63 |
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | BLM | P54132 | 1/20 | 0.61 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11937071 | 0.92 | SIGMAR1 (0.59) | SIGMAR1EBPTP53CYP1A2CYP3A4 | |
| SCHEMBL2743258 | 0.89 | SIGMAR1 (0.67) | SIGMAR1EBPTP53CYP1A2CYP3A4 | |
| SCHEMBL12084851 | 0.87 | SIGMAR1 (0.57) | SIGMAR1EBPTP53CYP1A2CYP3A4 | |
| SCHEMBL17339943 | 0.85 | SIGMAR1 (0.56) | SIGMAR1EBPTP53CYP1A2CYP3A4 | |
| SCHEMBL18192167 | 0.85 | SIGMAR1 (0.60) | SIGMAR1EBPTP53CYP1A2CYP3A4 | |
| SCHEMBL31052615 | 0.85 | SIGMAR1 (0.60) | SIGMAR1EBPTP53CYP1A2CYP3A4 | |
| SCHEMBL8129805 | 0.83 | SIGMAR1 (0.58) | SIGMAR1EBPTP53CYP1A2CYP3A4 | |
| SCHEMBL8557477 | 0.83 | SIGMAR1 (0.84) | SIGMAR1EBPTP53CYP1A2CYP3A4 | |
| SCHEMBL11704179 | 0.83 | SIGMAR1 (0.58) | SIGMAR1EBPTP53CYP1A2CYP3A4 | |
| SCHEMBL30291382 | 0.83 | SIGMAR1 (0.58) | SIGMAR1EBPTP53CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10611786-B2 | Manganese (III) catalyzed C—H aminations | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2020-04-07 | — | — | US | disclosed |
| US-20190106448-A1 | MANGANESE (III) CATALYZED C--H AMINATIONS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2019-04-11 | — | — | US | disclosed |
| US-20190106448-A1 | MANGANESE (III) CATALYZED C--H AMINATIONS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2019-04-11 | — | — | US | disclosed |
| US-8492563-B2 | 4,5,6,7-tetrahydrobenzo[B]thiophene derivatives and their use as sigma receptor ligands | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2013-07-23 | — | — | US | disclosed |
| US-8492563-B2 | 4,5,6,7-tetrahydrobenzo[B]thiophene derivatives and their use as sigma receptor ligands | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2013-07-23 | — | — | US | disclosed |
| US-8304423-B2 | Modulators of muscarinic receptors | VERTEX PHARMACEUTICAL INCORPORATED (US) | 2012-11-06 | — | — | US | disclosed |
| US-8304423-B2 | Modulators of muscarinic receptors | VERTEX PHARMACEUTICAL INCORPORATED (US) | 2012-11-06 | — | — | US | disclosed |
| US-20120238567-A1 | 4,5,6,7-TETRAHYDROBENZO[B]THIOPHENE DERIVATIVES AND THEIR USE AS SIGMA RECEPTOR LIGANDS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2012-09-20 | — | — | US | disclosed |
| US-20120238567-A1 | 4,5,6,7-TETRAHYDROBENZO[B]THIOPHENE DERIVATIVES AND THEIR USE AS SIGMA RECEPTOR LIGANDS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2012-09-20 | — | — | US | disclosed |
| US-20120196857-A9 | Modulators of Muscarinic Receptors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-08-02 | — | — | US | disclosed |
| US-20090099222-A1 | Modulators of muscarinic receptors | VERTEX PHARMACEUTICALS INCORPORATED | 2009-04-16 | — | — | US | disclosed |
| WO-2009045519-A1 | MODULATORS OF MUSCARINIC RECEPTORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-04-09 | — | — | WO | disclosed |
| US-7351706-B2 | Indol-3-yl-carbonyl-spiro-piperidine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2008-04-01 | — | — | US | disclosed |
| US-20070213315-A1 | Modulators of muscarinic receptors | VERTEX PHARMACEUTICALS INCORPORATED | 2007-09-13 | — | — | US | disclosed |
| US-20070213315-A1 | Modulators of muscarinic receptors | VERTEX PHARMACEUTICALS INCORPORATED | 2007-09-13 | — | — | US | disclosed |
| WO-2007100664-A2 | MODULATORS OF MUSCARINIC RECEPTORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-09-07 | — | — | WO | disclosed |
| US-20070155761-A1 | Vasopressin receptor antagonists; dysmenorrhea, hypertension, chronic heart failure, liver cirrhosis, nephrotic syndrome, obsessive compulsive disorder, anxiety; antidepressants; 1'-{[6-Chloro-1-(3,5-difluorobenzyl)-1H-indol-3-yl]carbonyl}spiro[3,1-benzoxazine-4,4'-piperidin]-2(1H)-one | HOFFMANN-LA ROCHE INC. | 2007-07-05 | — | — | US | disclosed |
| EP-1511728-B1 | OXOPHENYL-CYCLOHEXYL-PROPANOLAMINE DERIVATIVES, PRODUCTION AND USE THEREOF IN THERAPEUTICS | SANOFI AVENTIS (FR) | 2007-03-14 | — | — | EP | disclosed |
| EP-0414289-B1 | Spirocyclic antipsychotic agents | MERCK SHARP & DOHME (GB) | 1994-02-23 | — | — | EP | disclosed |
| EP-0414289-A1 | Spirocyclic antipsychotic agents | MERCK SHARP & DOHME LTD. (GB) | 1991-02-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099222-A1 | Modulators of muscarinic receptors | CHRM3, CHRM5, CHRM2 | SIGMAR1 237/4885EBP 2877/4885TP53 4383/4885 |
| US-20070213315-A1 | Modulators of muscarinic receptors | CHRM3, CHRM5, CHRM2 | SIGMAR1 237/4885EBP 2877/4885TP53 4383/4885 |
| US-20120238567-A1 | 4,5,6,7-TETRAHYDROBENZO[B]THIOPHENE DERIVATIVES AND THEIR USE AS SIGMA RECEPTOR LIGANDS | SIGMAR1, TMEM97, OPRM1 | SIGMAR1 1/4885EBP 364/4885TP53 4633/4885 |
| US-10611786-B2 | Manganese (III) catalyzed C—H aminations | HLCS, NCL, NUDC | SIGMAR1 3247/4885EBP 1612/4885TP53 1233/4885 |
| US-20070155761-A1 | Vasopressin receptor antagonists; dysmenorrhea, hypertension, chronic heart failure, liver cirrhosis, nephrotic syndrome, obsessive compulsive disorder, anxiety; antidepressants; 1'-{[6-Chloro-1-(3,5-difluorobenzyl)-1H-indol-3-yl]carbonyl}spiro[3,1-benzoxazine-4,4'-piperidin]-2(1H)-one | AVPR2, OXTR, AVPR1A | SIGMAR1 86/4885EBP 2132/4885TP53 4479/4885 |
| US-20190106448-A1 | MANGANESE (III) CATALYZED C--H AMINATIONS | HLCS, NCL, NUDC | SIGMAR1 3307/4885EBP 2013/4885TP53 1014/4885 |
| US-20120196857-A9 | Modulators of Muscarinic Receptors | CHRM3, CHRM5, CHRM2 | SIGMAR1 237/4885EBP 2877/4885TP53 4383/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.